Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (101-110 of 324) with videos related to

Pageof 33
Sort By:
Controlled Clinical Trials|April 12, 2002
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRITSean Emery, Donald I Abrams, David A Cooper, et al.
Plos One|June 15, 2010
Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast AsiaAlexander Hoare, Stephen J Kerr, Kiat Ruxrungtham, et al.
Molecular Therapy. Nucleic Acids|October 28, 2015
Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional SilencingChantelle Ahlenstiel, Catalina Mendez, Steven T H Lim, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 26, 2003
Rates of transmission of antiretroviral drug resistant strains of HIV-1Palanee Ammaranond, Philip Cunningham, Robert Oelrichs, et al.
Plos One|September 8, 2011
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53Steven N Reuland, Nathaniel B Goldstein, Katie A Partyka, et al.
Plos One|October 20, 2017
HIV dynamics linked to memory CD4+ T cell homeostasisJohn M Murray, John Zaunders, Sean Emery, et al.
AIDS (London, England)|January 25, 2003
No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001Palanee Ammaranond, Philip Cunningham, Robert Oelrichs, et al.
Antiviral Therapy|August 20, 2003
Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patientsPeter G Cardiello, Tarika Samor, David Burger, et al.
The Journal of Infectious Diseases|March 20, 2004
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virusGregory J Dore, David A Cooper, Anton L Pozniak, et al.
AIDS (London, England)|January 26, 2005
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugsJintanat Ananworanich, Zewlan Moor, Umaporn Siangphoe, et al.
Pageof 33

Showing results (101-110 of 324) with videos related to

Sort By:
Pageof 33
Controlled Clinical Trials|April 12, 2002
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRITSean Emery, Donald I Abrams, David A Cooper, et al.
Plos One|June 15, 2010
Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast AsiaAlexander Hoare, Stephen J Kerr, Kiat Ruxrungtham, et al.
Molecular Therapy. Nucleic Acids|October 28, 2015
Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional SilencingChantelle Ahlenstiel, Catalina Mendez, Steven T H Lim, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 26, 2003
Rates of transmission of antiretroviral drug resistant strains of HIV-1Palanee Ammaranond, Philip Cunningham, Robert Oelrichs, et al.
Plos One|September 8, 2011
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53Steven N Reuland, Nathaniel B Goldstein, Katie A Partyka, et al.
Plos One|October 20, 2017
HIV dynamics linked to memory CD4+ T cell homeostasisJohn M Murray, John Zaunders, Sean Emery, et al.
AIDS (London, England)|January 25, 2003
No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001Palanee Ammaranond, Philip Cunningham, Robert Oelrichs, et al.
Antiviral Therapy|August 20, 2003
Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patientsPeter G Cardiello, Tarika Samor, David Burger, et al.
The Journal of Infectious Diseases|March 20, 2004
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virusGregory J Dore, David A Cooper, Anton L Pozniak, et al.
AIDS (London, England)|January 26, 2005
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugsJintanat Ananworanich, Zewlan Moor, Umaporn Siangphoe, et al.
Pageof 33